摘要
目的 观察苯那普利和倍他乐克对治疗充血性心力衰竭 (CHF)患者的临床疗效。方法 选择慢性CHF患者 10 2例随机分组 ,设A组为常规疗法组 ,B组为常规疗法基础上加用苯那普利 (2 .5～ 10mg ,1次 /d)和倍他乐克 (6 .2 5～ 2 5mg ,2次 /d)组 ,观察其治疗前后心、肾功能变化及再入院率。结果 (1)B组患者第 6和 12个月因心衰再入院率分别为 2 3.1%和 30 .8% ,而A组相应期间的再入院率分别为 4 2 .0 %和 6 0 .0 % ,差异有统计学意义 (P <0 .0 5和P <0 .0 1)。 (2 )经治疗 6～ 12个月后 ,两组心率(HR)、左室射血分数 (LVEF)和血肌酐 (Cr)较治疗前均有明显改善 (P <0 .0 1)。治疗后两组间比较 ,B组LVDd缩小较A组显著(P <0 .0 1)。结论 苯那普利和倍他乐克治疗CHF ,可明显降低患者再入院率 ,改善心功能。
Objective To evaluate the clinical efficacy of benazepril and metoprolol in the treament of congestive heart failure(CHF). Methods 102 patients with CHF were divided into two groups. Group A was given routine therapy .Group B was given benazepril (2.5～10mg once a day ) and metoprolol (6.25～25mg twice a day ) in addition to routine therapy. A 6 to 12 months follow up was done on the dynamic functions of heart and kidney, frequency of readmission . Results At the 6 th and 12 th month, hospital readmission rates were 23.1% and 30.8% in group B vs. 42.0% and 60.0% in group A ( P <0.05 and <0.01,respectively).In comparison with the baseline values, after 6 to 12 months teatment,there was a significant improvement of renal function and left ventricular ejective fraction ( P <0.01). The reduction of LVDd in group B was more remarkable than group A ( P <0.01). Conclusion The patients with CHF could benefit from bnazepril and metoprolol treatment by lowering the frequency of hospital readmission, and can improve cardiac function and resist the development of CHF.
出处
《重庆医学》
CAS
CSCD
2003年第1期18-19,共2页
Chongqing medicine
